跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR
Authorized
STANDARD
TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR
teva canada limited
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
64aad5b5a01f1e4f
Company
teva canada limited
Type
Standard
Approval Details
Approval Id
64aad5b5a01f1e4f
Drug Approval Canada Name
TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR
Product Name
TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR
Status
Marketed
Status Date
2017-07-26
Original Market Date
2017-07-26
Din
02393549
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
08:18.08.16
Atc Original
J05AR06 EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ
Atc Name
j 05 ar 06
Aig Number
0352327001
Company Name
teva canada limited
Company Address
30 Novopharm Court, Toronto, Ontario, Canada, M1B 2K9
Active Ingredients
EMTRICITABINE
200 MG
EFAVIRENZ
600 MG
TENOFOVIR DISOPROXIL FUMARATE
300 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
64aad5b5a01f1e4f
Type
Standard
Back to Health Canada Approvals